Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Current Leases (2019 - 2025)

Historic Current Leases for Bolt Biotherapeutics (BOLT) over the last 7 years, with Q3 2025 value amounting to $2.7 million.

  • Bolt Biotherapeutics' Current Leases fell 439.09% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 439.09%. This contributed to the annual value of $2.3 million for FY2024, which is 1908.7% down from last year.
  • Bolt Biotherapeutics' Current Leases amounted to $2.7 million in Q3 2025, which was down 439.09% from $2.6 million recorded in Q2 2025.
  • Bolt Biotherapeutics' 5-year Current Leases high stood at $3.0 million for Q2 2024, and its period low was $1.6 million during Q1 2021.
  • For the 5-year period, Bolt Biotherapeutics' Current Leases averaged around $2.5 million, with its median value being $2.5 million (2023).
  • Per our database at Business Quant, Bolt Biotherapeutics' Current Leases skyrocketed by 6662.23% in 2021 and then plummeted by 1908.7% in 2024.
  • Bolt Biotherapeutics' Current Leases (Quarter) stood at $2.5 million in 2021, then decreased by 4.4% to $2.4 million in 2022, then increased by 16.35% to $2.8 million in 2023, then decreased by 19.09% to $2.3 million in 2024, then rose by 19.95% to $2.7 million in 2025.
  • Its Current Leases was $2.7 million in Q3 2025, compared to $2.6 million in Q2 2025 and $2.4 million in Q1 2025.